0 items Products FabRICATOR FabRICATOR Enzyme FragIT & FragIT Kit FabRICATOR LE FabRICATOR Validation Kit Anti-FabRICATOR FabRICATOR Z FabRICATOR Z Enzyme FragIT Z & FragIT Z Kit FabULOUS FabULOUS Enzyme FabULOUS Fab kit GingisKHAN GingisKHAN Enzyme GingisKHAN Fab kit GingisREX IgGZERO IgGZERO Enzyme deGlycIT GlycINATOR GlyCLICK Services Applications SmartEnzyme Reference Tool Antibody Characterization Antibody Drug Conjugates Charcterization Antibody Oxidation Antibody Subunit Fragmentation FabRICATOR in QC Applications mAb Quality in Cell Culture Mass Spectrometric Analysis of Antibodies Deglycosylated IgG Degree of Fucosylation Enhancing mAb Efficacy Mass Spectrometric Analysis of Antibodies Preparative Applications Production of Fab Fragments Generation of F(ab’)2 Fragments Contact How to Order Support FAQ Store Antibody Fragmentation Glycosidases Proteases About Careers Investor Blog Careers About Genovis Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. Genovis was founded in 1999 and has since developed several unique SmartEnzymes that facilitate development and quality control of i.a. biological drugs. The products enable customers to conduct faster analyses with higher quality than competing technologies can offer. In addition to the physical product, all customersreceive technical support and Genovis also offers development of customized methods. The company has well-equipped facilities in which to conduct efficient product development in the early research phase, as well as subsequent development of production processes and the final product format. An important cornerstone and competitive advantage of Genovis’ R&D activities is collaboration with academic groups that focus on characterizing new enzymes. Just as valuable is the customer relationship that enables product development to meet customer needs. The Group consists of Genovis AB, Sweden, and the wholly owned subsidiary Genovis Inc., USA. Genovis operations in Sweden includes 13 employees. The company has 2,500 shareholders and the company's shares are listed on Nasdaq Stockholm First North. Find more information at Investor Relations EMEA & Asia Genovis AB Box 790 SE-220 07 Lund Sweden 0046 (0)46 101230 USA & Canada Genovis Inc 245 First Street, suite 1800 Cambridge, MA 02142 USA (617) 444-8421 Customer Support How to order FAQ Contact support Terms & Conditions References Products Online store Corporate About us Investor relations Contact IR Facebook LinkedIn We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok